SureTrader Advertisement
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: BigKahuna, BooDog, TOB, sox040713, Astavakra, TheHound
Search This Board:
Last Post: 7/24/2016 9:44:34 PM - Followers: 706 - Board type: Free - Posts Today: 0

Cellceutix Corporation (CTIX)
 

 

http://cellceutix.com/
 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@cellceutix.com
 
About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Brilacidin is also being evaluated in a Phase 2 Proof-of-Concept trial as a novel treatment for Ulcerative Proctitis. Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com. 

Management:  http://cellceutix.com/team/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://cellceutix.com/pipeline/

 

 
Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX
 
http://cellceutix.com/category/press-release/

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

http://eccmid.meetingexpert.net/ECCMID_546/poster_122533/program.aspx/anchor122533

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

http://eccmid.meetingexpert.net/ECCMID_546/poster_122353/program.aspx

 
SEC Filings (CIK:0001355250):  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com/

 
Share Structure:  See SEC filing link above for current share structure
 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275

 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet


http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations:  info@cellceutix.com

Following is a WEEKLY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CTIX News: Insider Financial Publishes New Research On Three Promising Biotechs 07/16/2016 08:00:00 AM
CTIX News: Securities Registration: Employee Benefit Plan (s-8) 07/15/2016 04:52:11 PM
CTIX News: Securities Registration: Employee Benefit Plan (s-8) 07/15/2016 04:50:06 PM
CTIX News: Current Report Filing (8-k) 07/14/2016 08:11:43 AM
CTIX News: Statement of Changes in Beneficial Ownership (4) 07/11/2016 01:03:04 PM
PostSubject
#155456  Sticky Note Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For wild4ctix 07/21/16 07:15:58 AM
#155327  Sticky Note Cellceutix advancing as a mid stage biopharmaceutical company. BooDog 07/19/16 07:31:34 AM
#155230  Sticky Note Some Due Diligence on B-UP sox040713 07/18/16 12:53:34 PM
#155181  Sticky Note $CTIX NEWS ---> 7-18-16 Cellceutix Receives Update on TheHound 07/18/16 10:10:20 AM
#151674  Sticky Note An ever quickening pace of achievement.... rmzport 06/15/16 09:36:03 PM
#117003  Sticky Note Cellceutix released efficacy data for Kevetrin, its cancer TOB 08/09/15 03:05:24 PM
#155652   Very excited for the start of 04 A.B. scottsmith 07/24/16 09:44:34 PM
#155651   Thanks... I was looking for just one location KarinCA 07/24/16 08:55:12 PM
#155650   The proof can be found in this PR. "the sox040713 07/24/16 08:30:38 PM
#155649   350 mg of Prurisol was proven to be sox040713 07/24/16 08:00:23 PM
#155648   Perfect. You must live a charmed life. CTIX. Detonate 07/24/16 07:04:01 PM
#155647   I saw the bioavailability #'s used by KMBJN KarinCA 07/24/16 06:51:43 PM
#155646   I got the numbers about Prurisol here. https://clinicaltrials.gov/ct2/show/NCT0 sox040713 07/24/16 06:13:40 PM
#155645   The Mako hit piece was misguiding investors. This sox040713 07/24/16 06:03:17 PM
#155644   Good post that I fully agree with. KarinCA 07/24/16 02:39:39 PM
#155643   we probably will get better updates on K. govorchin 07/24/16 01:55:40 PM
#155642   Wonderful post!! djs7 07/24/16 01:30:33 PM
#155641   if not SP comes down and does not SJ2016 07/24/16 01:19:33 PM
#155640   IMO, honesty is the best policy. CallMeCrazy 07/24/16 12:57:06 PM
#155639   Ctix mgmt should find ways to increase SP Amatuer17 07/24/16 11:54:05 AM
#155638   Dr B has given us a wonderful update govorchin 07/24/16 10:45:31 AM
#155637   Perfect, Hahahaha. Ain't it the SAD truth ? wild4ctix 07/24/16 10:00:39 AM
#155636   "misguiding to any new investors that come to F1ash 07/24/16 09:34:55 AM
#155635   I will be jumping in those water in vip1999 07/24/16 09:04:21 AM
#155634   I'll be in your area in December!! r37049 07/24/16 08:45:24 AM
#155632   Amatuer17 It points to a lack of cancer medicines Echo20 07/24/16 07:51:36 AM
#155631   My man! BIzzy 07/24/16 01:18:26 AM
#155630   Sitting on my lanai with a Black Grouse BigKahuna 07/24/16 01:17:48 AM
#155629   How this is anyway related to CTIX? It does Amatuer17 07/24/16 12:29:42 AM
#155628   Below please find reposted instructions to KarinCA for Barron4664 07/23/16 11:39:16 PM
#155626   CTIX Bloomberg - Facing Cancer Drug Shortage, U.S. Relies Echo20 07/23/16 07:32:43 PM
#155624   Bk How many orphan designations does CTIX have? Echo20 Echo20 07/23/16 06:10:11 PM
#155623   The PolyMedix purchase of assets didn't include Prurisol. KarinCA 07/23/16 06:02:08 PM
#155622   Kevetrin is an interesting drug and may have DesireToLearn 07/23/16 05:57:17 PM
#155621   The real strength of our position is not Tails 07/23/16 02:11:23 PM
#155620   Barron would you mind reposting the instructions? stevo99 07/23/16 01:49:33 PM
#155619   Dr. Shapiro, Sir what are your thoughts on tombrady12nh 07/23/16 12:04:22 PM
#155618   I must say the following. Lord knows scottsmith 07/23/16 12:03:57 PM
#155617   Well put! thefamilyman 07/23/16 11:44:29 AM
#155616   I couldn't agree more and I am excited Jhawker 07/23/16 11:28:48 AM
#155615   As I understand it, the current budget was F1ash 07/23/16 11:01:25 AM
#155613   That's pretty intelligent. Whether you believe it DesireToLearn 07/23/16 10:05:42 AM
#155612   I mean as the cash balance declines I DesireToLearn 07/23/16 10:02:05 AM
#155609   BK is not accusing you of FUD. And frrol 07/23/16 09:23:43 AM
#155608   You still haven't explained what you mean by BigKahuna 07/23/16 02:56:01 AM
#155605   Not trying to promote FUD. I actually own DesireToLearn 07/23/16 02:16:17 AM
#155604   Precisely the opposite of what actually happens, providing BigKahuna 07/22/16 10:54:35 PM
#155602   No. That's just you trying to generate FUD. thefamilyman 07/22/16 10:48:49 PM
#155601   Just think that the closer it gets the DesireToLearn 07/22/16 10:39:51 PM
#155600   The company has access to enough funding to thefamilyman 07/22/16 09:24:46 PM
#155599   Thanks Detonate. Ive never seen anyone comment on Barron4664 07/22/16 08:59:00 PM
#155598   While B is on hold wondering if the DesireToLearn 07/22/16 08:15:08 PM
#155597   FINRA short sales of CTIX AlanC 07/22/16 06:55:07 PM
#155596   Barron4664, I think a few of us CTIX Detonate 07/22/16 05:38:08 PM
#155595   A solid 17% bounce from the $1.12 low sox040713 07/22/16 05:01:26 PM
#155594   6 consecutive days of buying. Are we going septmike09 07/22/16 04:31:24 PM
PostSubject